Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perindopril for Fontan-associated nephropathy
ACTRN12624000648527Phase 4Not yet recruiting
- Sponsor
- Heart Foundation
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of perindopril in Fontan-associated nephropathy (FAN) and Cardiovascular Malformation (CVM) (2 arms), sponsored by Heart Foundation. Primary endpoint: Urine albumin-creatinine ratio. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
perindopril
03
Conditions
Fontan-associated nephropathy (FAN)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on ACTRN12624000648527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000648527.